- Case Report
- Open Access
Malignant perivascular epithelioid cell tumor (PEComa) of the femur: a case report and literature review
Diagnostic Pathology volume 10, Article number: 54 (2015)
We describe a case of malignant perivascular epithelial cell tumor (PEComa) arising primarily in the distal left femur of a 47-year-old male.
The patient presented with pain accompanied by progressive swelling of his left thigh. Computed tomography (CT) scan and magnetic resonance imaging (MRI) revealed an osteolytic lesion. Curettage of the lesion was reported as a clear cell tumor with recommendation for exclusion of a metastatic clear cell carcinoma. However, thorough examinations did not find any primary site elsewhere, apart from the presence of bilateral pulmonary metastases. Evaluation of the submitted H & E slides identified a malignant PEComa which was further confirmed by subsequent immunohistochemical study.
The occurrence of PEComa as a primary bone lesion is extremely rare. We present here a malignant PEComa of the distal left femur, and summarize the clinicopathological characteristics of this rare entity with literature review.
The virtual slide (s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5729035221600545.
Perivascular epithelioid cell tumor (PEComa) represents a family of closely related entities showing both melanocytic and myoid differentiation, including angiomyolipoma, lymphangioleiomyomatosis, clear-cell ‘sugar’ tumor of the lung, and neoplasms arising in a wide variety of locations including skin, soft tissue and visceral organs called PEComa not otherwise specified (PEComa-NOS) . PEComa manifesting as a primary bone lesion is extremely rare. To date, only 10 convincing cases of primary bone origin have been reported in the English literature [2–8]. Although the majority of PEComas behave in a benign or indolent fashion, a minority of tumors exhibit aggressive behavior. The malignant variant may cause diagnostic pitfalls, particularly in interpretation of biopsy specimens. In this report, we describe a case of malignant PEComa arising primarily in the femur to broaden the anatomic spectrum of primary bone PEComas.
A 47-year-old male presented with a 2-year history of pain and progressive swelling of his left thigh. Computed tomography (CT) scan and magnetic resonance imaging (MRI) of the left lower limb revealed an osteolytic lesion in the distal femur (Figs. 1a and b), measuring 5.2 × 3.2 × 2.6 cm in size. The lesion showed destruction of the cortex with extension into the surrounding skeletal muscle. Curettage of the lesion was performed which was initially reported as a clear cell tumor with recommendation for the exclusion of a metastatic clear cell carcinoma. No evidence of a primary tumor in any site elsewhere was identified by subsequent systematic examinations. However, CT scan of the chest revealed multiple nodules in bilateral lungs which were confirmed as metastatic by CT-guided core needle biopsy (Figs. 1c and d). The patient was treated with conservative palliative radiotherapy and systemic chemotherapy. He was alive with the disease at 3.5 year follow up.
Histologically, the tumor was composed of plump polygonal cells with abundant clear to palely eosinophilic or granular cytoplasm arranged in nests that were separated by a delicate aborizing or sinusoidal-type vasculature (Figs. 2a and b). The tumor cells showed a moderate to high degree of hypercellularity and nuclear atypia (Fig. 2c). A few multinucleated giant cells were also observed. Mitotic figures were readily encountered (5/50HPF). Occasional atypical mitotic figures were present. Areas of coagulative tumor necrosis were obvious within the tumor (Fig. 2d). Immunohistochemically, the tumor cells were strongly positive for HMB45 (Fig. 3a), PNL2, TFE3 and vimentin. Most tumor cells were also positive for alpha smooth muscle actin (Fig. 3b). There was weak staining of CD10 and CD117. CD34 staining clearly delineated the rich vascular network, highlighting the organoid or sinusoidal architecture. The tumor cells were negative for Melan-A, AE1/AE3, EMA, desmin and S100 protein.
The first case of primary bone PEComa was described by Insabato et al. in 2002 which occurred in the tibia of a 30-year-old male . The presentation of PEComa as a primary bone lesion is extremely rare. Taking the current case into account, there are only 11 cases of primary bone origin. The clinical features of these 11 primary bone PEComas are summarized in Table 1. The site of involvement includes right tibia in 3 cases [2, 6], right fibula in 3 cases [3, 4, 8], vertebral column in 2 cases (7th thoracic and 5th lumbar respectively) [6, 7], the sixth right rib , left acetabulum , and left femur (current case) in 1 case each. Like PEComas arising in other sites, primary bone PEComas also occurred in middle-aged adults with a mean age of 47 years and median age of 39 years (range, 26 to 93 years) respectively. Unlike PEComas of other sites which tended to have a female predilection, primary bone PEComas were distributed approximately equally in both sexes. This disparity is possibly due to the limited number of bone PEComas being reported thus far. In accordance with the very low frequency of TSC-associated PEComas, none of the patients with bone PEComas had association with TSC.
Clinically, patients with bone PEComas typically presented with pain. Three patients were accompanied with swelling [3, 8], one of whom had a pathologic fracture of the distal fibula . One patient was accompanied with bilateral leg weakness because of cord compression . Radiologically, primary PEComas of bone frequently appeared as osteolytic lesions. In more aggressive cases, destruction of cortex with forming of soft tissue mass could be noted [2, 6–8]. On MR imaging, the tumor was usually hypointense on T1-weighted imaging and hyperintense on T2-weighted images [6, 8]. In a biopsy-proven malignant PEComa, F-18 FDG PET demonstrated intense hypermetabolism . Of note, FDG PET scans were often negative in patients with benign PEComas and positive in malgiant PEComas . However, a benign PEComa of the lungs with extensive FDG uptake has also been described .
Histologically, most bone PEComas were composed of epithelioid perivascular cells that exhibited characteristic nesting or organoid arrangement. Two case were composed of both epithelioid and spindle cells . Of 11 cases, 3 were considered to be benign which were also supported by the clinical outcome [2, 4, 6, 8]. One case was supposed to have malignant potential based on the invasion into the surrounding connective tissues and overexpression of cyclinD1 . The remaining 7 cases were recognized histologically as fully malignant. Besides permeative growth pattern, marked nuclear atypia was present in all 7 cases, necrosis was seen in 2 cases (including the current case) , and mitotic activity was noted in 6 cases, ranging from 5/50HPF to 36/50HPF . Vascular invasion was identified in 2 cases [3, 6]. It is worthy to note that although most cases of malignant PEComa fulfilled the morphological criteria for malignancy proposed by Folpe et al. , rare example existed which was not clearly malignant on histological ground, especially on biopsy specimens . In such instance, the malignancy was usually betrayed by its aggressive clinical behaviour.
The major differential diagnosis in the current case includes metastatic clear cell carcinoma, especially of renal origin. However, immunohistochemical study ruled out this possibility as the tumor cells failed to express epithelial markers. Alveolar soft part sarcoma (ASPS), a sarcoma characterized by organoid pattern and sinusoidal-type vasculature, may cause confusion with PEComa. In particular, both tumors can express TFE3 [4, 12]. The absence of melanocytic differentiation in ASPS is helpful in the separation of these two entities. The other lesions that may enter the differential diagnoses are metastatic malignant melanoma and clear cell sarcoma. In addition to morphological differences, strong S100 protein and negative staining of myogenic markers in most melanomas and clear cell sarcomas (CCS), the presence of specific EWSR1 ATF1 fusion transcripts resulting from t (12:22) (q13; q12) in CCS are helpful features to distinguish the lesions from PEComa.
It seems that malignant PEComa of bone has a tendency to develop metastatic disease. Of 7 malignant bone PEComas, four developed metastatic disease, including pelvic bone metastases in one case , and lung metastases in other 3 cases (including the current case) [7, 8]. At present, the optimal therapy for malignant PEComa remains a challenging practice. The activation of the mTOR signaling pathway was thought mechanistically to be linked to the development of both TSC-associated and non-TSC-associated PEComa . Based on this pathologic mechanism, mTOR inhibitors (sirolimus/rapamycin) was applied in small number of cases and considered to be a rational molecular target for therapy in malignant PEComa . One patient with a malignant PEComa of the left acetabulum tried five cycles of temsirolimus with a favorable response of the suspected pulmonary metastases. However, the patient passed away eight months postoperatively despite several months of additional treatment .
We have described the clinicopathological and immunohistochemical features of a malignant PEComa arising primarily in the femur of an adult male. Although very rare, PEComa can present as a primary bone lesion. Clinical and pathological correlation is mandatory in arriving at the correct diagnosis.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.
Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologicstudy of 26 cases and review of the literature. Am J Surg Pathol. 2005;29(12):1558–75.
Insabato L, De Rosa G, Terracciano LM, Fazioli F, Di Santo F, Rosai J. Primary monotypic epithelioid angiomyolipoma of bone. Histopathology. 2002;40(3):286–90.
Lian DW, Chuah KL, Cheng MH, Yap WM. Malignant perivascular epithelioid cell tumour of the fibula: a report and a short review of bone perivascular epithelioid cell tumour. J Clin Pathol. 2008;61(10):127–1129.
Righi A, Dimosthenous K, Rosai J. PEComa: another member of the MiT tumor family? Int J Surg Pathol. 2008;16(1):16–20.
Torii I, Kondo N, Takuwa T, Matsumoto S, Okumura Y, Sato A, Tanaka F, Nishigami T, Hasegawa S, Tsujimura T. Perivascular epithelioid cell tumor of the rib. Virchows Arch. 2008;452(2):697–702.
Yamashita K, Fletcher CD. PEComa presenting in bone: clinicopathologic analysis of 6 cases and literature review. Am J Surg Pathol. 2010;34(11):1622–9.
Kazzaz D, Khalifa M, Alorjan M, Shaw M, Rezajooi K, Saifuddin A. Malignant PEComa of the lumbar vertebra: a rare bone tumour. Skeletal Radiol. 2012;41(11):1465–8.
Desy NM, Bernstein M, Nahal A, Aziz M, Kenan S, Turcotte RE, et al. Primary perivascular epithelioid cell neoplasm (PEComa) of bone: report of two cases and review of the literature. Skeletal Radiol. 2012;41(11):1469–74.
Rakheja R, Abikhzer G, Alabed YZ, Nahal A, Lisbona R. The appearance of osseous PEComa on F-18 FDG PET/CT. Clin Nucl Med. 2012;37(2):190–2.
Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, et al. Utility of _18F_2-fluoro-2- deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009;136(3):926–33.
Zarbis N, Barth TF, Blumstein NM, Schelzig H. Pecoma of the lung: a benign tumor with extensive 18 F-2-deoxy-D-glucose uptake. Interact Cardiovasc Thorac Surg. 2007;6(5):676–8.
Pang LJ, Chang B, Zou H, Qi Y, Jiang JF, Li HA, Hu WH, Chen YZ, Liu CX, Zhang WJ, Li F.Alveolar soft part sarcoma: a bimarker diagnostic strategy using TFE3 immunoassay and ASPL-TFE3 fusion transcripts in paraffin-embedded tumor tissues. Diagn Mol Pathol. 2008;17(4):245-52.
Kenerson H, Folpe AL, Takayama TK, Yeung RS. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol. 2007;38(9):1361–71.
Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010;28(5):835–40.
The authors declared no potential conflicts of interest with publication of this case report.
IWL drafted the report, contributed to concept. LY and JW contributed to concept and design. All authors approved the final version of the manuscript.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Lao, I.W., Yu, L. & Wang, J. Malignant perivascular epithelioid cell tumor (PEComa) of the femur: a case report and literature review. Diagn Pathol 10, 54 (2015). https://doi.org/10.1186/s13000-015-0292-2
- Perivascular epithelioid cell tumor (PEComa)
- Bone neoplasm